ProjectGAPVAC – Glioma Actively Personalized Vaccine Consortium / CIMT partner

Basic data

Acronym:
GAPVAC
Title:
Glioma Actively Personalized Vaccine Consortium / CIMT partner
Duration:
01/11/2012 to 01/11/2016
Abstract / short description:
The Glioma Actively Personalized VAccine Consortium (GAPVAC) is the first EU-funded initiative aimed at clinically developing biomarker-guided actively personalized vaccines (APVACs) to treat cancer patients.
Keywords:
Glioblastoma
immunotherapy
Immuntherapie
Peptide vaccine

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Institut for Immunology
Non-clinical institutes, Faculty of Medicine

Contact persons

Faculty of Medicine
University of Tübingen
Institut for Immunology
Non-clinical institutes, Faculty of Medicine
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions
Institut for Immunology
Non-clinical institutes, Faculty of Medicine

Local organizational units

Immunology †
Interfaculty Institute for Cell Biology (IFIZ) †
Interfaculty Institutes

Funders

Brüssel, Belgium
Help

will be deleted permanently. This cannot be undone.